Understanding what is behind the trabecular meshwork
March 09, 2022
A complete understanding can help ophthalmologists get better results for their patients.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Glaucoma Insights
Sight Sciences announces first patient treated in TRIDENT European trial
March 28, 2022
Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject in lowering IOP as a standalone treatment option without concomitant cataract surgery.
Study: Minorities with glaucoma facing cost barriers to medication
March 04, 2022
In advance of World Glaucoma Week March 6-12, a study of 3826 patients with glaucoma has found significantly higher odds of self-reported difficulty affording medication observed among non-Hispanic African American and Hispanic individuals compared with non-Hispanic White individuals.
Protein may protect brain cells impacted by glaucoma
March 02, 2022
A team of investigators found that sigma 1 receptor, which is known to protect cells from stress, could turn out to be key to the function and survival of the neurons most impacted by glaucoma.
Eliminating nonadherence: Leaving the glaucoma drops in the dust
March 02, 2022
The glaucoma toolbox is expanding to include laser, drug delivery systems, and minimally invasive glaucoma surgery.
Study: Elios combined with cataract surgery, delivers significant IOP reduction out to 8 years
February 22, 2022
The company is revealing the 8-year follow up results of its novel Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery.
Heidelberg Engineering supporting Glaucoma/Myopia OCT Phenotyping Consortium
February 01, 2022
The GMOPC was established in February 2020 at an inaugural meeting in Los Angeles, California, as an investigator-initiated clinical research study, with Heidelberg Engineering as an industry partner.
LKC Technologies unveils enhanced PhNR protocol for improved, objective glaucoma testing and tracking
January 27, 2022
According to the company, the protocol enhancement for the RETeval Device marks an important step in mitigating vision loss from glaucoma.
Simplifying glaucoma medical therapy for our patients
January 24, 2022
Numerous studies have shown that adherence declines with more complex regimens of more than 1 or 2 bottles.
Surgery developed by ophthalmologist at Dean McGee Eye Institute proves its effectiveness
December 21, 2021
Mahmoud A. Khaimi, MD, developed a minimally invasive glaucoma surgery known as ab-interno canaloplasty as a treatment option between topical therapies and invasive surgery. The technique continues to prove its value.